Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Pembro
NCT03126812Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2017
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Netherlands Cancer Institute. Primary endpoint: Number of T-cells in peripheral blood. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03126812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126812.